
Oyster Therapeutics
British protein-degrader biotech targeting tau in Alzheimer's; formerly Kesmalea, raised $60m in 2026.
Last refreshed: 14 November 2026 · Appears in 1 active topic
Can a degrader small enough to enter the brain clear tau?
Timeline for Oyster Therapeutics
Closed a $60m Series A
UK Startups and Innovation: Oyster brings Eli Lilly into $60m roundBackground
Oyster Therapeutics, the British biotech formerly called Kesmalea, closed a $60m Series A round on 10 November 2026 led by London's 4BIO Capital. Eli Lilly joined as a new strategic investor, beside TOHO Ventures, which Global Brain manages.
Oyster develops protein degraders: drugs that tag a faulty protein for the cell's own disposal system. Its lead programme is an oral degrader aimed at tau, the protein that tangles inside nerve cells in Alzheimer's disease. Its bet is that a small enough degrader can cross the barrier that protects the brain. Syncona and Oxford Science Enterprises backed the company before the rename.
Lilly, which sells the amyloid antibody Kisunla, backed two British biotech rounds in five days, both times as a minority investor behind a specialist lead.
Who invested in Oyster Therapeutics?
What happened to Kesmalea Therapeutics?
What drug is Oyster Therapeutics developing?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.